Arnold Bakker
Johns Hopkins University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arnold Bakker as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:42 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06919926 · Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older AdultsJohns Hopkins University · active not recruiting · Hippocampal Overactivity, Dementia · study director
- Ph2NCT05824728 · Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related PsychosisJohns Hopkins University · active not recruiting · Parkinson Disease Psychosis · study director
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:42 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 3 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Biomarkers of Cognitive Decline Among Normal Individuals: The BIOCARD CohortU19AG033655 · NIA · JOHNS HOPKINS UNIVERSITY · fiscal years 2026 · $4,753,674 awarded in 2026Same name and institution; not confirmed by an ID
- Core F: Imaging Biomarker CoreP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · fiscal years 2020 to 2026 · $474,467 awarded in 2026Same name and institution; not confirmed by an ID
- Visual hallucinations and memory impairment in Parkinson's Disease: The role of hippocampal networksR01MH123552 · NIMH · JOHNS HOPKINS UNIVERSITY · fiscal years 2021 to 2025 · $621,339 awarded in 2025Same name and institution; not confirmed by an ID
- Imaging the alpha7 nicotinic acetylcholine receptor in mild cognitive impairmentR01AG065202 · NIA · JOHNS HOPKINS UNIVERSITY · fiscal years 2020 to 2024 · $753,105 awarded in 2024Same name and institution; not confirmed by an ID
- Hippocampal and parietal network changes among subjects in the early phases of AD and relationship with CSF biomarkersP50AG005146 · NIA · JOHNS HOPKINS UNIVERSITY · fiscal years 2015 to 2019 · $196,503 awarded in 2019Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- A Phase 3 Pivotal Trial of AGB101 to Slow Progression in MCI due to Alzheimer's DiseaseR01AG061091 · NIA · AGENEBIO, INC. · PI RICHARD Charles MOHS · fiscal years 2018 to 2022Named on NCT06919926
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:42 UTC. The ranking covers the 200 most relevant of 46 PubMed records, and a shared surname and initials can bring in a namesake. All 46 on PubMed
- Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment.Neuron · 2012748 citationsRCR 22.8
- 354 citationsRCR 5.5
- Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance.Neuroimage Clin · 2015225 citationsRCR 7.9
- 156 citationsRCR 5.2
- A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators.Acta Psychiatr Scand · 1997130 citationsRCR 5.9
- Failure of new biochemical markers to exclude acute myocardial infarction at admission.Lancet · 1993114 citationsRCR 4.4
- 110 citationsRCR 1.9
- Efficacy and safety of high-dose baclofen for the treatment of alcohol dependence: A multicentre, randomised, double-blind controlled trial.Eur Neuropsychopharmacol · 2016100 citationsRCR 4.9
- 92 citationsRCR 2.5
- Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.Arthritis Rheum · 201273 citationsRCR 1.9